Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4508 in advanced non-small cell lung cancer
NCT07003321Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4508 in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Primary endpoints: Adverse Events and Serious Adverse Events at 2 years and Objective Response Rate at 1 year. Started Sep 2025; status: recruiting.
02
Drugs
HRS-4508
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07003321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003321.